London, UK – 22 June 2026 – Sorbie Bornholm LP (“Sorbie”), a UK investment partnership, is pleased to announce that it has entered into a new CAD$8,000,000 Sharing Agreement with Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (OTCQX: MDNAF), in connection with an equity investment in the Company. The Sharing Agreement is structured so that Medicenna can access additional, non-dilutive capital as its share price appreciates over time, with no pre-set upper limit on the additional proceeds the Company may receive above an agreed benchmark price across the 18-month term of the agreement. Completion of the investment and the Sharing Agreement remains subject to customary closing conditions, including receipt of applicable regulatory and stock exchange approvals.
The investment is intended to support the continued advancement of Medicenna’s pipeline of next-generation immunotherapies, which are designed to direct the body’s own immune system to attack cancer more precisely and with fewer side effects than treatments currently available to patients. Funding will support the ongoing Phase 1/2 ABILITY-1 clinical study of the Company’s lead drug candidate, MDNA11; the advancement of its second candidate, MDNA113, toward first-in-human testing; and continued partnering efforts for bizaxofusp, its most advanced program.
Medicenna is a clinical-stage biotechnology company that develops a class of engineered immune-signaling proteins it calls Superkines. Its lead candidate, MDNA11, is an enhanced version of interleukin-2 (IL-2), a natural protein that switches on cancer-killing immune cells. In the ongoing ABILITY-1 study, MDNA11 has produced meaningful tumor responses in roughly 30-40% of patients with hard-to-treat solid tumors, including several whose cancers had already stopped responding to other leading immunotherapies. The Company’s second candidate, MDNA113, is a first-in-class treatment designed to concentrate its activity within the tumor; preclinical data presented at the 2026 American Association for Cancer Research (AACR) meeting showed it could be given safely at doses 30-fold higher than a competing anti-PD-1 IL-2 agent. Medicenna’s most advanced program, bizaxofusp, is ready for late-stage (Phase 3) testing in recurrent glioblastoma, an aggressive brain cancer, and has received Fast Track and Orphan Drug designations from U.S. and European regulators.
Medicenna is advancing quickly across its pipeline. Over the next one to two years, the Company expects to complete patient enrollment in the ABILITY-1 study and report additional MDNA11 clinical data, seek regulatory guidance on a potential registration-enabling trial, file an IND to begin first-in-human testing of MDNA113, and continue pursuing a partnership for bizaxofusp. The Company’s longer-term goal is to establish itself as a leader in Superkine-based medicines and to provide safer, more effective options for cancer patients whose disease no longer responds to today’s most widely used therapies.
Cynthia Pussinen, Managing Director, Biotechnology Investments for Sorbie Bornholm LP, noted:
“Medicenna is moving quickly and executing aggressively across a differentiated Superkine platform, and MDNA11’s activity in patients who have exhausted other leading immunotherapies is exactly the kind of progress our model is built to reward. A Sharing Agreement aligns our interests directly with the Company’s: as Medicenna delivers on its catalysts and the market recognizes that execution, it can access additional, non-dilutive capital, without Sorbie taking a board seat or standing in the way of future financings. That alignment is what makes the structure a strong fit for a team executing at this pace.”
The details of the investment and Sharing Agreement can be viewed here on the Company’s website.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing a new generation of cancer treatments called Superkines, engineered versions of natural immune-system proteins built to fight cancer more precisely. Its programs, led by MDNA11, MDNA113 and bizaxofusp, are built on the Company’s proprietary Superkine, BiSKIT and T-MASK platforms and are focused on helping patients whose cancers have stopped responding to existing therapies.
For more information on Medicenna Therapeutics Corp., please visit medicenna.com or contact:
Daniel Scarr, Investor Relations
ir@medicenna.com
About Sorbie Bornholm LP
Sorbie Bornholm is a global investment firm that provides long-term growth capital to listed micro, small, and mid-cap companies. Through our Sharing Agreement, issuers receive long-term capital and the opportunity for additional, non-dilutive proceeds tied directly to share price performance against an agreed-upon Benchmark Price. The model rewards operational excellence without adding to the share structure.
For over 25 years, Founder and CEO Greg Kofford and his team have partnered with management teams at a stage when reliable capital is hard to find and the right capital structure matters most. That experience shapes how we function. We bring capital and perspective, but the decisions belong to management. We do not take board seats or seek control, and the Sharing Agreement is structured so that when our portfolio companies succeed, Sorbie does too. Finance That Rewards Growth is not just marketing. It is the mechanism behind everything we do.
To see if a Sharing Agreement is right for your company, please contact Sorbie Bornholm:
Cynthia Pussinen, Managing Director, Biotechnology Investments
+1-646-954-0107
cynthiap@sorbiebornholm.com
DISCLAIMER: The information in this article is issued by Sorbie Bornholm for informational purposes only. It does not constitute a communication by Sorbie Bornholm, or any associate of Sorbie Bornholm, or an invitation or inducement to engage in an investment, nor is it a solicitation to buy or sell any investment or an agreement by Sorbie Bornholm to enter into any contract or agreement. This news release contains forward-looking statements, including statements regarding completion of the investment and Sharing Agreement and any additional proceeds issuers may receive. There can be no assurance that the investment or Sharing Agreement will be completed, or as to the total proceeds issuers may ultimately receive. See Terms of Use.
